---
schema_version: "secwatch.filing_event.v1"
accession: "0001831283-22-000071"
form_type: "8-K"
ticker: "LIANY"
cik: "0001831283"
company_name: "LianBio"
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:44:52.871062+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# LianBio Q3 net loss $21.9M; cash $331.8M; mavacamten Phase 3 data expected mid-2023

## Summary
- Net loss of $21.9M for Q3 2022 vs $13.1M YoY; R&D expenses $8.3M, G&A $16.3M.
- Cash, cash equivalents, securities $331.8M at Sep 30, 2022, down from $403.2M Dec 31, 2021; runway into 2H 2024.
- Mavacamten Phase 3 EXPLORER-CN data expected mid-2023; NDA submitted in Hong Kong; included in Chinese HCM guidelines.
- TP-03 Phase 3 LIBRA trial for Demodex blepharitis initiated in China; data expected Q4 2023; US NDA accepted, PDUFA Aug 25, 2023.
- Phase 3 NANORAY-312 (NBTXR3) for head & neck cancer initiated in Asia; Phase 1 BBP-398 dosing begun.

## SEC filing metadata
- accession: 0001831283-22-000071
- form_type: 8-K
- ticker: LIANY
- cik: 0001831283
- company_name: LianBio
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831283/000183128322000071/0001831283-22-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831283/000183128322000071/lian-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001831283-22-000071
- JSON: https://secwatch.observer/filing/0001831283-22-000071.json
- Plain text: https://secwatch.observer/filing/0001831283-22-000071.txt

## Key facts
- Earnings Releases
  LianBio reported third quarter ended September 30, 2022 results: net income $21.9 million.
  - Period: third quarter ended September 30, 2022
  - Net income: $21.9 million
  - Result: reported results
  source text: LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831283/000183128322000071/0001831283-22-000071-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.